Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

SkylineDx Collaborates with Flanders Institute of Biotechnology to Validate Biomarkers forImmunotherapy Response

NextEdge Admin

14 Nov 2023

2 min 12 sec

SkylineDx announced its collaboration with the Flanders Institute of Biotechnology (VIB) on a groundbreaking project, POINTILLISM 2.0, aimed at validating biomarkers for immune checkpoint blockade response in cancer patients. This collaboration, funded through the VIB Grand Challenges Program, seeks to advance socially impactful science. The research, spanning three years, will build upon the findings of SkylineDx’s predecessor project, POINTILLISM 1.0.

Researchers from SkylineDx, Researchers(KU Leuven), and the University Hospital Leuven will undertake four clinical trials focusing on breast cancer, recurrent cervical carcinoma, head and neck cancer, and melanoma. Patients will contribute blood and tumor samples before and during treatment. The samples will be analyzed using cutting-edge single-cell multiomics technologies to create spatial maps of the tumor ecosystem. Leveraging this data, the team aims to identify predictive biomarkers for response and resistance to immune checkpoint inhibitors and propose effective combination regimens.

The collaboration with VIB-KU Leuven’s Center for Cancer Biology will provide valuable insights into the tumor microenvironment, cellular and molecular cancer mechanisms, and business development expertise. The POINTILLISM 2.0 project addresses a critical gap by seeking biomarkers that can predict patient responses or resistance to therapy, potentially reducing healthcare costs by sparing nonresponders from severe adverse events associated with immune checkpoint inhibitor therapy. The societal impact of this research could be significant, offering a promising avenue for personalized cancer treatment strategies.